ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will p
… momentum toward the clinic Accelerated development of Axiomer™ for CNS applications via new research partnership … on RNA editing, ProQR made important progress with Axiomer, our ADAR-mediated RNA editing technology platform,” …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … ProQR and further supports the confidence we have in our Axiomer technology,” said Daniel A. de Boer, Founder and CEO … with meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides. Key data reported …
… directed toward high conviction targets utilizing ProQR’s Axiomer technology INDIANAPOLIS; LEIDEN, Netherlands; and … announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the …
Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 P
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform, today reported its … at the RNA Editing Summit in Boston, highlighting its Axiomer technology platform and AX-0810, the Company’s … with meaningful changes in biomarkers in NHPs using Axiomer RNA Editing Oligonucleotides. At ASGCT, ProQR and …
